RU2011134486A - Агент, повышающий экспрессию редокс-факторов - Google Patents

Агент, повышающий экспрессию редокс-факторов Download PDF

Info

Publication number
RU2011134486A
RU2011134486A RU2011134486/15A RU2011134486A RU2011134486A RU 2011134486 A RU2011134486 A RU 2011134486A RU 2011134486/15 A RU2011134486/15 A RU 2011134486/15A RU 2011134486 A RU2011134486 A RU 2011134486A RU 2011134486 A RU2011134486 A RU 2011134486A
Authority
RU
Russia
Prior art keywords
redox
thioredoxin
expression
redox factor
agent
Prior art date
Application number
RU2011134486/15A
Other languages
English (en)
Other versions
RU2606856C2 (ru
Inventor
Мисато СУГАХАРА
Юдзи КАЦУТА
Дзётаро НАКАНИСИ
Сэм У. ЛИ
Original Assignee
Сисейдо Компани, Лтд.
Те Дженерал Хоспитал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сисейдо Компани, Лтд., Те Дженерал Хоспитал Корпорейшн filed Critical Сисейдо Компани, Лтд.
Publication of RU2011134486A publication Critical patent/RU2011134486A/ru
Application granted granted Critical
Publication of RU2606856C2 publication Critical patent/RU2606856C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)

Abstract

1. Агент, повышающий экспрессию редокс-фактора, который содержит в качестве активного ингредиента кемпферол, кверцетин, их гликозиды или любые их комбинации.2. Агент, повышающий экспрессию редокс-фактора по п.1, в котором редокс-фактор представляет собой одно или более веществ, выбранных из группы, состоящей из тиоредоксина, тиоредоксинредуктазы, глутатионредуктазы и глутаредоксина.3. Агент, повышающий экспрессию редокс-фактора, который в качестве активного ингредиента содержит экстракт из листьев гинкго, экстракт галанги (Kaempferia galanga) или любые их комбинации.4. Агент, повышающий экспрессию редокс-фактора по п.3, в котором редокс-фактор представляет собой одно или более веществ, выбранных из группы, состоящей из тиоредоксина, тиоредоксинредуктазы, глутатионредуктазы и глутаредоксина.

Claims (4)

1. Агент, повышающий экспрессию редокс-фактора, который содержит в качестве активного ингредиента кемпферол, кверцетин, их гликозиды или любые их комбинации.
2. Агент, повышающий экспрессию редокс-фактора по п.1, в котором редокс-фактор представляет собой одно или более веществ, выбранных из группы, состоящей из тиоредоксина, тиоредоксинредуктазы, глутатионредуктазы и глутаредоксина.
3. Агент, повышающий экспрессию редокс-фактора, который в качестве активного ингредиента содержит экстракт из листьев гинкго, экстракт галанги (Kaempferia galanga) или любые их комбинации.
4. Агент, повышающий экспрессию редокс-фактора по п.3, в котором редокс-фактор представляет собой одно или более веществ, выбранных из группы, состоящей из тиоредоксина, тиоредоксинредуктазы, глутатионредуктазы и глутаредоксина.
RU2011134486A 2010-01-29 2011-01-28 Агент, повышающий экспрессию редокс-факторов RU2606856C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29958910P 2010-01-29 2010-01-29
US61/299,589 2010-01-29
PCT/JP2011/051811 WO2011093469A1 (ja) 2010-01-29 2011-01-28 レドックス関連因子発現促進剤

Publications (2)

Publication Number Publication Date
RU2011134486A true RU2011134486A (ru) 2013-02-27
RU2606856C2 RU2606856C2 (ru) 2017-01-10

Family

ID=44319447

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011134486A RU2606856C2 (ru) 2010-01-29 2011-01-28 Агент, повышающий экспрессию редокс-факторов

Country Status (9)

Country Link
US (1) US20110189318A1 (ru)
EP (1) EP2529736A4 (ru)
JP (1) JP5833438B2 (ru)
KR (1) KR20120119976A (ru)
CN (1) CN102361637A (ru)
BR (1) BRPI1100012A2 (ru)
RU (1) RU2606856C2 (ru)
TW (1) TWI572353B (ru)
WO (1) WO2011093469A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU91412B1 (en) * 2008-01-30 2009-07-31 Wurth Paul Sa Charging device for distributing bulk material
JP2016006021A (ja) * 2014-06-20 2016-01-14 株式会社ノエビア チオレドキシン関連因子発現促進剤
JP2016088905A (ja) * 2014-11-07 2016-05-23 健治 椛島 上皮又は粘膜に投与される組成物
WO2016132483A1 (ja) * 2015-02-18 2016-08-25 学校法人福岡大学 ヒトキマーゼ阻害剤及びヒトキマーゼの活性が関与する疾患の予防治療用薬剤
JPWO2022075096A1 (ru) * 2020-10-07 2022-04-14
JP6860739B1 (ja) * 2020-11-20 2021-04-21 ジェイ−ネットワーク，インコーポレイテッド 表皮内の抗酸化物質の発現増強剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0769862A (ja) * 1993-09-01 1995-03-14 Kao Corp 入浴剤組成物
JP3578858B2 (ja) 1995-12-11 2004-10-20 株式会社ノエビア 皮膚外用剤
US6471972B1 (en) * 1996-11-07 2002-10-29 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
US20040043047A1 (en) * 1999-03-26 2004-03-04 Parfums Christian Dior Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of the CD44 membrane receptors of skin cells
US20040101578A1 (en) * 2001-08-03 2004-05-27 Min-Young Kim Compositon containg ginkgo biloba that inhibit angiogenesis and matrix metalloprotinase
JP2007510725A (ja) * 2003-11-05 2007-04-26 オステオスクリーン，インコーポレイテッド イチョウフラバノイド類による発毛の刺激
JPWO2006033351A1 (ja) 2004-09-22 2008-05-15 レドックス・バイオサイエンス株式会社 チオレドキシン発現誘導用組成物
KR20060080376A (ko) * 2005-01-05 2006-07-10 하수용 무기 광물 용해액 및 식물 추출물을 포함하는 화장료조성물 및 그의 제조 방법
US20060165812A1 (en) * 2005-01-21 2006-07-27 Amershire Investment Corporation Method and topical formulation for treating headaches
KR100665966B1 (ko) * 2005-09-23 2007-01-09 장정만 규산염과 은행잎추출물로 제조되는 입욕제의 조성물 및제조제법
JP2007284430A (ja) 2006-03-20 2007-11-01 Rohto Pharmaceut Co Ltd グルタチオン産生促進剤
JP2007269671A (ja) 2006-03-30 2007-10-18 Redox Bioscience Inc アレルギー性皮膚炎の予防ないし治療剤
KR100892273B1 (ko) * 2007-04-25 2009-04-09 (주)아모레퍼시픽 캄페롤-3-ｏ-루티노사이드를 유효 성분으로 함유하는 피부외용제 조성물
JP2009132662A (ja) * 2007-11-30 2009-06-18 Maruzen Pharmaceut Co Ltd グルタチオン産生促進剤

Also Published As

Publication number Publication date
CN102361637A (zh) 2012-02-22
TW201136587A (en) 2011-11-01
TWI572353B (zh) 2017-03-01
US20110189318A1 (en) 2011-08-04
JP5833438B2 (ja) 2015-12-16
KR20120119976A (ko) 2012-11-01
WO2011093469A1 (ja) 2011-08-04
EP2529736A1 (en) 2012-12-05
BRPI1100012A2 (pt) 2016-05-03
EP2529736A4 (en) 2013-07-10
JPWO2011093469A1 (ja) 2013-06-06
RU2606856C2 (ru) 2017-01-10

Similar Documents

Publication Publication Date Title
RU2011134486A (ru) Агент, повышающий экспрессию редокс-факторов
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
UA95283C2 (ru) Активное косметическое начало, состоящее из экстракта микроводорослей класса chlorophyceae и феррулата аргинина, и его применение
MA33045B1 (fr) Composition pharmaceutique contenant de la linagliptine et facultativement un inhibiteur sglt-2, et ses utilisations
ECSP11010905A (es) Uso de ditiina-tetracarboximidas para combatir hongos fitopatógenos
CL2013000322A1 (es) Compuestos derivados de piperidina sustituida; proceso de preparacion; composicion farmaceutica y su uso para producir un efecto antiproliferativo y/o proapoptotico.
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
NO20073889L (no) Fast farmasoytisk sammensetning omfattende Valsartan
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
TR201004346T2 (tr) Depresyon ve anksiyetenin tedavisinde farmasötikal kompozisyonlar.
EP2319488A3 (en) Compositions comprising an NFkB-inhibitor and a tropoelastin promoter
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
WO2012024395A3 (en) Compositions comprising paulwnin and/or paulownia extracts and uses thereof
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
TR200900882A2 (tr) Tadı ve kokusu maskelenmiş, bıyoyararlanımı yüksek farmasotık bileşimler.
TR200900881A2 (tr) Tadı ve kokusu maskelenmiş stabil farmasötik bileşimler
GB2488493A (en) Sunless tanning with pyranones and furanones
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX2012008253A (es) Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.
CL2012003661A1 (es) Composición farmacéutica de liberación sostenida que comprende un compuesto derivado de 2-feniltiazol; y uso en el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal.
AR082594A1 (es) Docosahexanoato de pantenilo y su uso para el tratamiento y prevencion de enfermedades cardiovasculares
FR2949060B1 (fr) Extrait de la plante alhagi pseudalhagi, compositions le contenant et leurs utilisations

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180129